Quantcast

Latest Clostridium histolyticum Stories

2014-06-25 16:26:44

LYNBROOK, N.Y., June 25, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, announced today that Swedish Orphan Biovitrum AB (Sobi) has filed for an extension of the label for XIAPEX (the EU trade name for collagenase clostridium histolyticum or CCH) with the European Medicines Agency (EMA) to include the indication of...

2014-05-19 20:21:42

LYNBROOK, N.Y., May 19, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced that new analyses of data evaluating the use of XIAFLEX in adult men with Peyronie's disease were presented by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) at the 2014 Annual...

2014-05-12 08:31:34

LYNBROOK, N.Y., May 12, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, today announced that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences. -- 2014 UBS Global Healthcare Conference (New York, NY)Monday, May 19, 2014 at 9:30 a.m. EDT -- Jefferies 2014 Global...

2014-05-01 08:36:53

LYNBROOK, N.Y., May 1, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®)( )in the EU, announced today that it will host a conference call and live audio webcast at 8:30 a.m. ET on Thursday, May 8, 2014 to report its first quarter 2014 financial results and provide a corporate update....

2014-04-28 08:31:12

Four Podium Sessions to Highlight New Analyses of Data from Pivotal Phase 3 Trials Evaluating XIAFLEX for the Treatment of Peyronie's Disease CHESTERBROOK, Pa., April 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced presentations from multiple trials evaluating the use of XIAFLEX® (collagenase clostridium histolyticum or CCH) in patients with Peyronie's disease (PD).These data will be presented at...

2014-04-14 12:32:51

Encore Data Highlighted from Trials Evaluating XIAFLEX, the First and Only FDA Approved Treatment for Peyronie's Disease CHESTERBROOK, Pa. and STOCKHOLM, April 14, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that encore data were presented from multiple clinical trials evaluating the use of XIAFLEX®/ Xiapex® (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). These...

2014-04-07 08:29:11

STOCKHOLM and CHESTERBROOK, Pa., April 7, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on April 3, 2014. Xiapex/ XIAFLEX® is a first-in-class biologic approved in the US, EU, Canada and Australia for the treatment of adult Dupuytren's contracture...

2014-02-27 08:30:09

LYNBROOK, N.Y., Feb. 27, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, today announced that it will host a conference call and live audio webcast at 8:30 a.m. EST on Thursday, March 6, 2014 to report its fourth quarter and full year 2013 financial results and provide a corporate update. In order to participate in the...

2014-02-24 08:27:24

PDUFA Date Scheduled for October 20, 2014 CHESTERBROOK, Pa., Feb. 24, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's submission of a supplemental Biologics License Application (sBLA) requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of two Dupuytren's contracture (DC)...

2014-02-19 16:24:56

LYNBROOK, N.Y., Feb. 19, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, today announced that BioSpecifics' President, Tom Wegman, will present at the following upcoming investor conferences. -- RBC Capital Markets' 2014 Global Healthcare Conference (New York, NY)Wednesday, February 26, 2014 at 4:05 p.m. EST --...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.